Unigene Laboratories has dosed the first subject in a Phase II study evaluating an experimental oral parathyroid hormone analogue as a treatment for osteoporosis in postmenopausal women.

Unigene is developing it’s the drug in partnership with GlaxoSmithKline, as part of an exclusive worldwide licensing agreement.

The multicentre, double blind, randomised, repeat-dose and placebo-controlled study will enroll 93 postmenopausal osteoporotic women and will include an open label comparator arm of Forsteo injectable formulation.

The primary endpoint will be an increase in bone mineral density at the lumbar spine at 24 weeks in patients following once-daily treatment with the orally delivered parathyroid hormone analogue, compared to baseline.

Secondary endpoints will assess biochemical markers of bone formation and resorption, as well as the safety, tolerability and pharmacokinetics of the oral formulation.

Patient enrolment is expected to be completed in the first half of 2011 and the company expects to report top-line results before the end of the year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.